Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

326.06 +1.31 (+0.40%)
Streaming Delayed Price Updated: 2:43 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Where Insulet Stands With Analysts
Via Benzinga
Insulet to Present at the Jefferies Global Healthcare Conference
From Insulet Corporation
Via Business Wire
NASDAQ:PODD, a strong growth stock, setting up for a breakout.
INSULET CORP (NASDAQ:PODD), a strong growth stock, setting up for a breakout. 
Via Chartmill
Is NASDAQ:PODD suited for growth investing?
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news. 
Via Benzinga
4 Analysts Assess Insulet: What You Need To Know
Via Benzinga
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains
Ride the coattails of institutional investors with these three overlooked stocks smart money investors are piling into for triple-digit gains. 
Via InvestorPlace
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Latest on Insulet and its legal battle with EOFlow. Understand the impact of the appellate court's decision on market dynamics and Insulet's future. 
Via Benzinga
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?
Wall Street is experiencing a subdued trading session, with all major indices showing minimal movement around midday in New York. 
Via Benzinga
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024
PODD stock results show that Insulet beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
From Insulet Corporation
Via Business Wire
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
7 Stable Stocks for 50% Returns by Early 2025
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries. 
Via InvestorPlace
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
5 Stocks To Buy On The Dip To Gain From The Wall Street Rally
Wall Street had a dream run in 2023, reversing the nightmare of 2022. The impressive bull run appears set to continue in 2024. Thus, here is a look at some stocks that may be worth buying on the dip... 
Via Talk Markets
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
From Insulet Corporation
Via Business Wire
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
From Insulet Corporation
Via Business Wire
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
Exposures US Equities
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.